No business profile yet.
Size Medcaptain Medical Technology (2041.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $378M, the 832nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.72 on 18 Nov 2026.
Growth Revenue grew 19.4% over the last twelve months (peer median +7.1%); the operating margin is 2.5% (peer median 12.2%).
Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.8× (5th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.7 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.94B | HK$1.76B | HK$1.52B | HK$1.45B | HK$1.07B |
| Revenue growth | — | +16% | +5% | +36% | — |
| Gross profit | HK$1.03B | HK$893M | HK$754M | HK$720M | HK$466M |
| EBITDA | HK$189M | HK$198M | HK$18.8M | HK$13.1M | -HK$198M |
| Net income | HK$10.4M | HK$53.0M | -HK$105M | -HK$70.4M | -HK$259M |
| Free cash flow | HK$196M | HK$104M | HK$57.2M | -HK$33.3M | HK$16.8M |
| Capital expenditure | HK$99.4M | HK$107M | HK$146M | HK$99.7M | HK$110M |
| Total debt | HK$495M | HK$455M | HK$460M | HK$604M | HK$561M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2041.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | -11.6% | 8th highest of 21 |
| Distance from 52-week high | -47.5% | -43.6% | 6th lowest of 21 |
| Revenue growth (TTM) | +19.4% | +7.1% | 6th highest of 21 |
| Operating margin | 2.5% | 12.2% | 7th lowest of 21 |
| EV / Sales | 1.5× | 3.8× | 5th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 17.1% | -4.2% | 5th most demanding of 14 |
| Growth delivered (Del g) | +18.1% | +5.6% | 4th highest of 14 |
| Hurdle (Req g minus delivered) | -1.0 pp | +1.8 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | -3.7 pp | +7.3 pp | 8th lowest of 20 |
| EV / EBITDA | 15.2× | 8.1× | 3rd most expensive of 10 |
| Net debt / EBITDA | -0.5× | -3.6× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | 7.1× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 1.4× | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 3.9× | 9.6% | +5.6% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |